Astrazeneca (AZN) closed the latest trading day at $76.32, indicating a -0.97% change from the previous session's end. This change lagged the S&P 500's 1.08% gain on the day. Meanwhile, the Dow ...

AstraZeneca is Thursday's pick for IBD 50 Growth Stocks To Watch as the biopharmaceutical name is holding up relatively well ...

AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for ...

AstraZeneca PLC has agreed to acquire EsoBiotec SA, a biotech company specializing in in vivo cell therapies. The $1 billion ...

Barclays analyst Emily Field maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £140.00. The ...

Wealthfront Advisers LLC acquired a new stake in AstraZeneca PLC (NASDAQ:AZN – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange ...

Healthcare giant AstraZeneca (AZN) is set to buy Belgian firm EsoBiotec for up to $1 billion. The deal aims to speed up progress in cell ...

The latest trading session saw Astrazeneca (AZN) ending at $77.47, denoting a -0.63% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily loss of 1.78%.

AZN's net leverage ratio strengthened further to close out 2024. Best of all, the stock looks to be undervalued. On February 6th, AZN shared its fourth-quarter earnings report for the period ended ...

AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from management regarding ongoing investigations at its China subsidiary.